News & Events

Investors

Month Year

E-mail Alerts

Nov 13, 2023

Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023

Late Breaking Poster Presentation Reports New Results Demonstrating Robust Liver Fat Reductions Across Key Subgroups, Including Patients with Type 2 Diabetes and Among Those with F2 or F3 Fibrosis...
Nov 2, 2023

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Oct 25, 2023

Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Fully Enrolled; Results Expected 1H24 Phase 2b VOYAGE Study Evaluating VK2809 for the...
Oct 23, 2023

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

13-Week Study to Evaluate the Safety and Efficacy of VK2735 Dosed Weekly Trial Size Increased from 125 to 176 Patients Due to Elevated Demand SAN DIEGO, Oct. 23, 2023 /PRNewswire/ -- Viking...
Oct 18, 2023

Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023

Conference Call Scheduled for Wednesday, October 25 at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 18, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage...